Status:

TERMINATED

Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)

Lead Sponsor:

Fondation Ophtalmologique Adolphe de Rothschild

Collaborating Sponsors:

University Hospital, Strasbourg, France

Centre Hospitalier Régional Metz-Thionville

Conditions:

COVID-19

Acute Respiratory Distress Syndrome

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study plans to learn more about the effects of Dornase Alfa in COVID19 (coronavirus disease of 2019) patients, the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2 ...

Detailed Description

Acute Respiratory Distress Syndrome (ARDS) is the most severe form of COVID-19 with a mortality reaching 50%. To date, no specific therapy has been shown to be effective. During an acute viral respira...

Eligibility Criteria

Inclusion

  • inclusion criteria
  • Adult patient (age ≥ 18 years old);
  • Hospitalized in intensive care ;
  • Severe COVID-19 pneumonia (positive diagnosis by RT-PCR or SARS-CoV-2 antigen test on nasopharyngeal or deep respiratory specimen and/or evocative thoracic scan: frosted glass opacities, consolidation, cross-linking, thickening of interlobular septa, peripheral nodules) with ARDS criteria according to Berlin criteria (PaO2/FiO2 ≤ 300 and PEP ≥ 5).
  • With respiratory assistance (intubated or NIV or ONHD) for less than 8 days;
  • With an expected duration of respiratory assistance \> 48 hours;
  • Carrier of an arterial catheter ;
  • For which 4 PaO2/FiO2 values on arterial blood over the last 24 hours are available;
  • Exclusion Criteria:
  • Known hypersensitivity to Dornase alfa or any of the excipients;
  • Pregnant or breastfeeding status;
  • Patient with legal protection.

Exclusion

    Key Trial Info

    Start Date :

    April 21 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 20 2021

    Estimated Enrollment :

    77 Patients enrolled

    Trial Details

    Trial ID

    NCT04355364

    Start Date

    April 21 2020

    End Date

    December 20 2021

    Last Update

    January 11 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Hôpital Fondation A. de Rotschhild

    Paris, France